AA
MLNT

AlphaMark Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

AlphaMark Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-390
Closed -$1K – 524
2019
Q3 		$1K Sell
390
-390
-50% -$1.41K ﹤0.01% 481
2019
Q2 		$5K Buy
+780
New +$2.97K ﹤0.01% 423

Other funds holding MLNT

Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

AlphaMark Advisors's MLNT Position: Q4 2019 in Review

AlphaMark Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 390 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in MLNT in Q2 2019 and held it in 2 quarters. The position peaked at $5K in Q2 2019. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

  • AlphaMark Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • AlphaMark Advisors sold 390 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1K.
  • AlphaMark Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • AlphaMark Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $5K in Q2 2019.
  • 37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on AlphaMark Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.